Related Experiment Video
Updated: Mar 30, 2026
06:18
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
13.0K
[Selective estrogen receptor modulators (SERMs)]
Nihon Rinsho. Japanese Journal of Clinical Medicine
|November 5, 2015
Summary
Selective estrogen receptor modulators (SERMs) offer bone benefits without cancer risks. These compounds, like raloxifene and bazedoxifene, effectively prevent bone loss in postmenopausal women.
Area of Science:
- Pharmacology and Endocrinology
- Bone Biology and Osteoporosis Research
Context:
- Postmenopausal osteoporosis is a significant health concern.
- Estrogen deficiency leads to bone loss and increased fracture risk.
- Traditional hormone replacement therapy carries risks of uterine and breast cancer.
Purpose:
- To evaluate the efficacy of selective estrogen receptor modulators (SERMs) in preventing and treating postmenopausal osteoporosis.
- To assess the tissue-selective effects of SERMs, specifically raloxifene and bazedoxifene.
- To determine if SERMs mitigate the negative effects of estrogen deficiency on bone health without increasing cancer risk.
Summary:
- Selective estrogen receptor modulators (SERMs), including raloxifene and bazedoxifene, were investigated for their effects on bone turnover and bone loss.
- These SERMs demonstrated inhibition of bone turnover and prevention of bone loss associated with estrogen deficiency.
- Importantly, SERMs did not affect uterine endometrial thickness and showed a beneficial effect on serum cholesterol levels.
Impact:
- SERMs represent a promising therapeutic strategy for managing postmenopausal osteoporosis.
- They offer a potential alternative to traditional hormone replacement therapy by providing skeletal benefits without associated cancer risks.
- Further research into SERMs could lead to improved treatments for bone health in postmenopausal women.
Related Concept Videos
01:31Transducer Mechanism: Nuclear Receptors
5.5K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
5.5K
01:25Dose-Response Relationship: Selectivity and Specificity
10.7K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
10.7K
01:00Enzyme-linked Receptors
88.9K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
88.9K
01:00Enzyme-linked Receptors
6.4K
6.4K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
559
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
559
01:27Transducer Mechanism: Enzyme-Linked Receptors
4.9K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
4.9K